BPG致力于知识的发现和传播
临床研究
©The Author(s) 2026.
世界华人消化杂志. 2026-01-28; 34(1): 51-61
在线出版 2026-01-28. doi: 10.11569/wcjd.v34.i1.51
表1 基线和治疗期间HBeAg(+)组与HBeAg(-)组的HBV参数纵向变化比较
All patientsHBeAg+HBeAg-P
例数(n)442420
性别(男/女)(27/17)(15/9)(12/8)0.865
年龄(year)38(31.5, 43)36(30.25, 39)39(34.5, 43)0.127
ALT(U/L)
基线160.65(71.25, 228.75)166.15(87.75, 279.7)145.5(60.5, 228.75)0.795
12 wk37.3(22.73, 54.75)35.3(25.92, 78.4)37.55(19.85, 48.45)0.316
96 wk18.6(12.08, 26.38)22.95(16.99, 29.16)13.72(11.63, 22.65)0.043
AST(U/L)
基线82(45.5, 136.5)80.5(48.75, 122.23)83.5(44.25, 148.5)0.832
12 wk30.5(26.08, 38.8)31.35(24.01, 37.9)29.35(26.08, 43.1)0.724
96 wk21.03(17.79, 24.93)21.47(17.79, 24.36)20.56(17.25, 25.98)0.981
TBIL(umol/L)
基线16.18(12.85, 23.85)15.35(11.8, 23.25)18.71(14.01, 24.6)0.472
12 wk14.4(11.06, 17.36)13.1(9.9, 17.38)15.47(12.45, 17.87)0.229
96 wk14.88(11.28, 20.77)12.71((10.25, 16.2)19.73(14.24, 29.35)0.012
HBsAg1
基线3.97(3.35, 4.39)4.22(3.59, 4.40)3.5(3.08, 4.17)0.018
12 wk3.92(3.41, 4.15)3.99(3.47, 4.27)3.70(3.34, 4.12)0.289
96 wk3.67(3.25, 3.87)3.64(3.26, 3.74)3.76(3.08, 3.92)0.671
HBeAg1
基线2.48(1.52, 2.92)2.73(2.26, 3.14)1.69(0.70, 2.71)0.01
12 wk0.36(-0.75, 1.56)1.47(0.36, 2.17)-0.74(-1.94, 0.34)<0.001
96 wk-0.30(-2, 0.81)0.59(-0.17, 1.33)-2(-2, -2)<0.001
HBcAb1
基线1.95(0.99, 2.15)1.08(0.97, 2.07)2.1(1.02, 2.76)0.073
12 wk1.99(1.38, 2.07)1.96(1.03, 2.06)2.01(1.63, 2.10)0.239
96 wk1.60(1.01, 2.11)1.12(0.97, 1.85)1.97(1.50, 2.11)0.027
高灵敏HBV DNA1
基线7.04(5.78, 7.97)7.03(5.92, 8.22)7.04(4.68, 7.76)0.48
12 wk2.38(1.48, 3.74)2.19(1.42, 3.76)2.51(1.60, 3.71)0.878
96 wk0.70(0.7, 1.45)0.91(0.7, 1.81)0.7(0.7, 1.03)0.192
HBcrAg3
基线7.00(6.85, 7.00)7.00(7.00, 7.00)6.9(6.18, 7.00)0.001
12 wk6.31(5.62, 7.00)6.63(6.14, 7.00)5.78(5.39, 6.67)0.005
96 wk5.67(4.71, 6.42)6.18(5.47, 6.81)4.71(4.34, 5.65)0.001
HBV RNA2
基线7.22(6.04, 7.83)7.49(6.43, 8.13)6.80(4.54, 7.48)0.034
12 wk5.58(4.24, 6.79)5.81(4.54, 7.01)4.71(3.35, 5.76)0.04
96 wk3.80(2.81, 5.34)4.54(3.36, 6.18)3.19(2.16, 4.56)0.022

引文著录: 刘斌, 杨柳, 康海燕, 杨莉, 刘云燕, 刘震霞, 党殿杰, 高永革, 李纯平, 李绍臣, 李敏然, 戴二黑. 血清HBcrAg、HBV RNA以及高灵敏HBV DNA预测恩替卡韦治疗慢性乙型肝炎患者疗效价值的比较. 世界华人消化杂志 2026; 34(1): 51-61
写信给帮助平台